As the first cause of Chinese residents’ death, malignant tumor occupies over 20% in all death causes. Meanwhile, cancer spectrum has gone through great changes: breast cancer and colorectal cancer rank among Top 10 most frequent malignant tumors; the incidence rates of pancreatic cancer and renal carcinoma are raised obviously; the incidence rates of gastric cancer and liver cancer remain high. In recent years, the annual growth of Chinese cancer patients is about 2 million.
By the end of 2008, there were 109.56 million people with the age of 65 and above in China, taking up 8.3% of the national total population and increasing by 0.2% YOY. The population aged 60 and above totaled 159.89 million, taking up 12% of the national total population and rising by 0.4% YOY. According to researches of some medical institutions in China, when the average age rises by one year, the incidence rate of malignant tumor grows by about 114/1000,000. The aging of population shows a positive correlation with the incidence rate of malignant tumor, leading to the increase of the incidence rate.
By the end of 2008, Chinese urbanization rate amounted to 45.7% with the urban population of 607 million. There were 655 cities with organizational structure, including 118 megalopolises with the population over 1 million. The acceleration of urbanization plays as a double-edged sword, improving residents’ income and living condition while intensifying their life pace and increasing the cancer incidence rate.
Moreover, the speed-up of urbanization aggravates Chinese environment pollution, raising the cancer incidence rate.
Chinese antitumor drug market scale maintains a high speed due to the rise of the cancer incidence rate. It is forecast that Chinese antitumor drug market scale will come up to RMB 42 billion (USD 6.16 billion) by 2010.
The high potentials on Chinese antitumor drug market attract more international pharmaceutical giants. Multinational pharmaceutical giants such as Roche have entered China.
In October 2009, a famous medical technology company of Europe put its anticancer drug – nemorubicin (in the phase II clinical research) on Chinese market for the first time, expecting to search for technology licensor in China which has the most liver cancer patients. The new drug technology sold publicly and competitively was originally researched by European largest medical R&D company to treat patients of primary carcinoma of liver. By October 2009, the new anti liver cancer drug had gone through hundreds of clinical experiments in Europe and North America. Moreover, it had entered the phase II clinical research in Chinese mainland through a Fortune 500 company.
The new drug patent holder is searching for the exclusive patent technology assignee in Chinese mainland. The rights and benefits of the assignee include: exclusive drug registration, API (active pharmaceutical ingredients) and injection production in Chinese mainland; sales permission in China and the Far East. However, the rights and benefits of the assignee subject to the final cooperation agreement.
As the new drug still stays in the phase II clinical research, the foreign side will consider the comprehensive strength of the assignee instead of the financial strength when choosing Chinese partner.
Chinese partner is expected to possess strong capacity in R&D, production and sales as well as certain international background. Namely, Chinese partner should be able to carry out market development in the Far East, especially Japan and South Korea.
For more information please visit:http://www.shcri.com/reportdetail.asp?id=259